ST2/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury

Area of Science:

• Neuroscience
• Immunology
• Cell Biology

Background:

• Interleukin-33 (IL-33) and its receptor ST2 are key players in immune regulation and inflammation.
• Their specific roles in ischemic brain injury, particularly post-stroke, remain incompletely understood.
• Microglia, the brain's resident immune cells, are critical in the response to ischemic events.

Purpose of the Study:

• To investigate the endogenous function of IL-33/ST2 signaling in the context of ischemic brain injury.
• To elucidate the mechanisms by which IL-33/ST2 signaling influences microglial responses and neuroprotection.
• To determine the impact of ST2 deficiency on stroke outcomes and neurological deficits.

Main Methods:

• Transient middle cerebral artery occlusion (tMCAO) model in mice to induce ischemic stroke.
• Assessment of IL-33 and ST2 expression in brain tissue post-ischemia.
• Evaluation of stroke outcomes (infarction size, neurological deficits) in ST2-deficient and wild-type mice.
• Intracerebroventricular administration of IL-33 and assessment of its therapeutic effects.
• Flow cytometry to analyze microglial polarization (M1/M2 markers).
• In vitro studies using primary microglia cultures and co-culture systems to examine IL-33/ST2-mediated signaling and IL-10 production.
• Experiments involving IL-10 knockout mice to confirm the role of IL-10 in neuroprotection.

Main Results:

• IL-33 expression increased in astrocytes and oligodendrocytes after tMCAO.
• ST2 deficiency exacerbated brain infarction and neurological deficits following ischemic stroke.
• IL-33 administration attenuated brain infarction, indicating a protective role.
• ST2 was highly expressed on microglia, with expression increasing post-tMCAO.
• ST2 deficiency promoted M1 microglial polarization and impaired M2 polarization.
• IL-33/ST2 signaling in microglia enhanced IL-10 production and conferred neuroprotection against oxygen-glucose deprivation in vitro.
• IL-10 was essential for IL-33-mediated neuroprotection in vivo.

Conclusions:

• Endogenous IL-33/ST2 signaling acts as a crucial brake on ischemic brain injury progression.
• ST2 deficiency promotes detrimental M1 microglial responses, worsening stroke outcomes.
• IL-33/ST2 signaling confers neuroprotection by inducing IL-10 production from microglia, enhancing neuronal survival.